Related Experiment Video
Updated: Apr 5, 2026
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
ADAM9 in tumor biology: molecular functions, clinical implications, and therapeutic targeting
Kuo-Hao Ho1, Chao-Jung Wu2, Yi-Chieh Yang3
1Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Abstract:
A disintegrin and metalloproteinase 9 (ADAM9), a member of the ADAM family, is expressed across multiple organs and is crucial to multiple physiological processes. Increasing evidence implicates ADAM9 in cancer progression through extracellular matrix (ECM) remodeling, protein shedding, and tumor microenvironment modulation. This study comprehensively reviews the literature on the clinical significance of ADAM9 and the mechanistic roles of ADAM9 in cancer. The results of our pan-cancer analysis demonstrated that ADAM9 is frequently upregulated and consistently associated with poor prognosis across tumor types. The results of in silico analyses also revealed that increased ADAM9 expression is correlated with an immunosuppressive tumor microenvironment and the activation of cancer-promoting pathways, such as cell cycle progression, epithelial-mesenchymal transition (EMT), and metabolism. This study also reviewed therapeutic strategies targeting ADAM9 and evaluated their potential in cancer treatment. This review provides insights into ADAM9 as both a biomarker of malignancy and a promising therapeutic target.
Insights
A disintegrin and metalloproteinase 9 (ADAM9) is frequently upregulated in cancers, correlating with poor prognosis and an immunosuppressive tumor microenvironment. Targeting ADAM9 shows promise for novel cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- A disintegrin and metalloproteinase 9 (ADAM9) is a key enzyme involved in physiological processes.
- ADAM9 plays a role in cancer progression via extracellular matrix remodeling, protein shedding, and tumor microenvironment modulation.
Purpose of the Study:
- To comprehensively review the clinical significance and mechanistic roles of ADAM9 in cancer.
- To explore ADAM9 as a potential biomarker and therapeutic target.
Main Methods:
- Comprehensive literature review.
- Pan-cancer analysis of ADAM9 expression and patient prognosis.
- In silico analysis of ADAM9's correlation with tumor microenvironment and cancer-promoting pathways.
Main Results:
- ADAM9 is frequently upregulated across various tumor types, associated with poor prognosis.
- Increased ADAM9 expression correlates with an immunosuppressive tumor microenvironment.
- ADAM9 activation is linked to cancer-promoting pathways like EMT, cell cycle progression, and altered metabolism.
Conclusions:
- ADAM9 is a significant biomarker for malignancy.
- ADAM9 represents a promising therapeutic target for cancer treatment.
- Targeting ADAM9 may offer novel strategies for improving cancer therapy outcomes.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
12:14CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
Published on: June 2, 2022
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:23Abnormal Proliferation
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...